News
ITCI
80.39
-0.56%
-0.45
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
NASDAQ · 2d ago
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Goldman Sachs cut the price target for Lennar Corporation from $180 to $174. The price target was increased for NVIDIA Corporation. Deutsche Bank cut Domino’s Pizza, Inc. Price target from $580 to $500. JP Morgan increased Abercrombie & Fitch's price target to $194.
Benzinga · 4d ago
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
Intra-Cellular Therapies (NASDAQ:ITCI) underwent analysis by 11 analysts in the last quarter. The 12-month price targets, analyzed by analysts, offer insights with an average target of $99.18. The company is a biopharmaceutical company that develops drugs for treating diseases of the central nervous system.
Benzinga · 4d ago
How The Parts Add Up: VONE Targets $274
NASDAQ · 4d ago
Intra-Cellular Therapies Is Maintained at Buy by Needham
Dow Jones · 4d ago
Intra-Cellular Therapies Price Target Raised to $100.00/Share From $94.00 by Needham
Dow Jones · 4d ago
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100
Benzinga · 4d ago
Weekly Report: what happened at ITCI last week (0715-0719)?
Weekly Report · 4d ago
INTRA-CELLULAR THERAPIES INC <ITCI.O>: NEEDHAM RAISES TARGET PRICE TO $100 FROM $94
Reuters · 4d ago
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
NASDAQ · 07/17 10:20
Weekly Report: what happened at ITCI last week (0708-0712)?
Weekly Report · 07/15 09:22
Morgan Stanley Remains a Buy on Intra-Cellular Therapies (ITCI)
TipRanks · 07/12 12:26
Bank of America Securities Reaffirms Their Buy Rating on Intra-Cellular Therapies (ITCI)
TipRanks · 07/10 13:17
Intra-Cellular Therapies (ITCI) Receives a Buy from RBC Capital
TipRanks · 07/10 10:38
INTRA-CELLULAR THERAPIES INC <ITCI.O>: RBC RAISES TARGET PRICE TO $107 FROM $103
Reuters · 07/09 11:28
Caplyta: Poised for Blockbuster Status Amid Strong Sales and Expanding Indications
TipRanks · 07/08 12:15
Weekly Report: what happened at ITCI last week (0701-0705)?
Weekly Report · 07/08 09:23
Weekly Report: what happened at ITCI last week (0624-0628)?
Weekly Report · 07/01 09:23
Recent 11% pullback isn't enough to hurt long-term Intra-Cellular Therapies (NASDAQ:ITCI) shareholders, they're still up 409% over 5 years
Intra-Cellular Therapies, Inc. Shares are down 11% in the past week. The stock price is 409% higher than it was five years ago. The company has grown its revenue at a rate of 70% per year over the last five years. The market has pushed the share price up by 38% over the same period. Intra- cellular therapies has a good track record of outperforming the market over the long term.
Simply Wall St · 06/30 13:41
Buy Rating Affirmed for Intra-Cellular Therapies with Caplyta Poised for Blockbuster Success
TipRanks · 06/26 12:05
More
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about Intra-Cellular Therapies through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.